|
|
|
Venture 2008 - Phase 2 "Businessplan" |
 |
|
|
Teams phase 1 "Business idea" >>
Teams phase 2 "Businessplan"
In the second phase of Venture 2008 101 business plans
were submitted. 10 teams were awarded a prize money totalling 137'500
Francs. 1 team was awarded a special prize of 3'500 Francs.
If you would like to get in touch with a team, please
contact Venture. After
consultation with the team we’ll be happy to facilitate contact.
Main prize winners >>
Winners ranked on the 6th place >>
Special prize >>
Main prize winners
| 1. rank |
|
Optotune
Electronics/Optics
ETH Zurich
|
Optotune's goal is to revolutionize the market for
optical systems by providing the next generation
of adaptive optical elements.
Imagine, for instance, equipping an endoscope with
a miniaturized optical zoom or reducing the number
of objectives needed in microscopy down to only
one. Or how about an ultra-thin mobile phone with
a light-weight and power-efficient 5x optical zoom?
Optotune can make this vision a reality! Our patented
technology based on electroactive polymers enables
the implementation of a revolutionary lens with
tuneable focal length. Its principle is similar
to that of the human eye: instead of moving lenses
back and forth, we bend them by applying a voltage.
This additional degree of freedom simplifies the
design of focus and zoom systems in many applications,
outperforming existing solutions in size, cost,
power consumption and robustness.
|
| |
|
| 2. rank |
|
NeMoDevices
Medical technology
ETH Zurich
University of Zurich
|
Brain blood flow (cerebral blood flow; CBF) and oxygen
supply are the most important parameters for detecting secondary
brain injuries and to guide treatment of patients with stroke
and head trauma. CBF is a key parameter to improve therapy
and outcome of these patients.
NeMoDevices provides new disposable NeuroMonitoring systems,
based on near infrared spectroscopy extended with a light-absorbing
dye dilution mode for CBF monitoring. NeMoCBFsystems are
unique, delivering absolute CBF values together with other
parameters (intracranial pressure, temperature and oxygen).
There is no device in the market that is able to deliver
all the parameters that are crucial for accurate diagnosis
and treatment, at the bedside and in a user-friendly manner.
Based on 12 years of development at the University Hospital
and the ETH Zurich, the new method has been invented,
validated, and scientifically published. In 2007, NeMoDevices
GmbH was founded.
|
| |
|
| 3. rank |
|
Celeroton
Electronics
ETH Zurich
|
Electrical dental handpieces, drilling spindles for
micro-electronics, ultra-compact compressors for heat
pumps, renewable energy generation and next-generation
cars all need miniaturised ultra-high-speed electrical
drive systems that are not available on the market today.
Celeroton develops and manufactures such miniaturised
ultra-high-speed electrical drives and sells them to
original equipment manufacturers (OEMs).
The innovation lies in the interdisciplinary design,
developed at the ETH Zurich, including mechanics, electromagnetics,
electronics and software. This design enables high rotational
speeds – up to 1 million revolutions per minute
(rpm) – not achievable by standard drive systems.
Miniaturised ultra-high-speed electrical drives resolve
several industry needs such as lightweight and highly
compact systems, increased productivity and high efficiency.
Our drives replace volume and weight with speed across
all industries!
|
| |
|
| 4. rank |
|
Aleva Neurotherapeutics
Medical technology
EPF Lausanne
|
Aleva Neurotherapeutics has developed a proprietary technology
that enables significantly better therapies for a broad
range of neurological diseases. The treatment of Parkinson’s
Disease through Deep Brain Stimulation is an existing USD
600 million market and is Aleva’s first target market.
Using Aleva’s microDBS™ electrodes, neurosurgeons
and neurologists will see reduced surgical and follow-up
times, reimbursers will see a substantial reduction in
costs, and patients will benefit from a decrease in debilitating
side effects.
|
| |
|
| 5. rank |
|
kringlan composites
Materials
Zurich
|
kringlan develops process technologies for high-performance
fibre- reinforced thermoplastic materials, with a particular
focus on ring-shaped structures. Based on our proprietary
platform technologies, we are developing carbon fibre
reinforced automotive wheels that will weigh 50% less
than a normal light alloy wheel. kringlan wheels will
ensure considerable reduction in both fuel consumption
and carbon dioxide emissions, while at the same time
improving car performance. Our technologies were developed
with regard to high-volume production, so that we will
be able to offer our products at competitive prices.
Our platform technologies enable us to manufacture more
than just wheels: every highly sollicitated, ring-shaped
structure is for us a future application!
|
Winners ranked on the 6th place (in alphabetical order)
Advanced Metal Technology
Materials
ETH Zurich
|
Advanced Metal Technology (AMT) realizes industrial applications
for metallic glasses. Due to its exceptional mechanical
properties and forming ability this novel material holds
significant potential for many structural applications in
small dimensions (e.g., micro gears, sensor substrates,
watch components). AMT is a collaboration of the Laboratory
of Metal Physics and Technology at the ETH Zurich and awtec
AG.
The company is applying a new technology-transfer model
in which customers who invest in early-stage application
development are granted an exclusivity for their market
segment. AMT is currently running development projects
with 10 world market leaders, all operating in different
markets. Based on these projects a turnover of CHF 20
million is expected by 2014.
AMT is currently searching for investors in order to
build up a large scale production.
|
| |
|
Biodiagnostik
Pharma/Biotech
University of Bern
|
BioDiagnostik is positioned as an innovative niche player
in the area of “Personalized Medicine”. The
company has developed a unique technology which permits
molecular detection of gene activities in routinely fixed
tissue. BioDiagnostik has built two complementary business
units
(BUs) on this platform:
1. The Diagnostics BU represents the low-risk, “bread
and butter” business. The already validated lead product
(molecular risk assessment of breast cancer) guarantees
profitable growth right from the beginning. The test allows
assessment, ahead of the therapy, of the individual risk
of a patient to produce metastases. Thus, the result can
be included in deciding on the right therapy.
2. The promising Theragnostics BU develops predictive molecular
gene signatures to identify patients who respond best to
a specific drug. This allows developing highly effective
drugs with fewer side effects while shortening development
time and reducing costs.
|
| |
|
HelvaLab
Pharma/biotech
EPF Lausanne
|
HelvaLab proposes innovative solutions for cell culture.
In particular, HelvaLab provides culture dishes with
surfaces that imitate the viscoelastic properties present
in the human body. These culture substrates range from
the stiffness of bone to virtually the softness of brain.
HelvaLab’s novel culture dishes contribute
to the maintenance of appropriate cell phenotypes
throughout the culture process by making them ‘feel
at home’. This provides more homogeneous cell
populations and a higher yield in cell production
compared with standard culture. Moreover, specific
cell types that do not survive and grow on conventional
culture dishes can now be observed in culture using
the HelvaLab technology.
|
| |
|
Preclin Ventures
Pharma/biotech
ETH Zurich
|
PRECLIN Ventures (PV) has developed an integrated
approach for the in vivo generation and pre-clinical
validation of therapeutics destined for treatment of
chronic inflammatory diseases. PV utilizes two core
technology platforms in its approach: (1) novel humanized
knock-in mice where the target mouse gene has been replaced
by its human counterpart; and (2) an unparalleled panel
of mouse models of human disease. Combined, these tools
provide a powerful platform for the rapid generation
and preclinical validation of therapeutics. To offset
the burn rate of the in-house research and development,
PV offers its ‘systems biology’ style approach
for the testing of external lead candidate drugs in
mouse models of inflammatory disease as a fee-for-service.
This approach can provide an overall drug efficacy snapshot
within 2 months – a strategy that can speed up
the preclinical phase of drug develop-ment up to 10
times, leading to a faster time to market.
|
| |
|
Siltectra
Energy
University of Zurich
Harvard University
|
Siltectra has developed proprietary technology that significantly
eliminates material losses when cutting crystalline silicon
into thin wafers.
Silicon wafers are the basis of most solar cells as well
as electronic ICs. Current cutting methods such as wire-sawing
waste almost 50% of the precious silicon raw material,
corresponding to a loss of over USD 2.1 billion per year
just for solar cells. Siltectra's breakthrough technology
avoids these losses altogether.
Siltectra will manufacture silicon wafers and first target
the USD 18 billion market for silicon solar cells. Using
Siltectra's wafers the costs for silicon solar cells can
be reduced by over 40%, allowing them to become cost-competitive
with fossil energy sources.
|
| |
|
Special prize
DJOM KOSSAM
Agriculture/food
ETH Zurich
|
DJOM KOSSAM is a dairy store in Bamako (Mali). It
is expanding into a dairy company that does not import
any milk powder. In order to provide costumers with
healthy dairy produce, we invest in the dairy value
chain. We ensure a regular income for farmers, associated
jobs for locals, and finally reach consumers known to
support the Malian economy. To achieve high milk quality,
employees and farmers will be educated and supervised
by local and international experts. Market access for
farmers, who can’t afford
their own cows, is facilitated by donations from the
project “buy your own cow in Mali”, initiated
by the association Pro Milk Mali. Increasing food prices
worldwide lead to a strong demand for local food in
developing countries. DJOM KOSSAM aims to provide many
people in Mali with healthy and microbiological safe
dairy products.
|
| |
|
|
|
